Company profile
Aureum Diagnostics
Aureums high-performance electrochemical sensor and handheld low-cost instrument platform enables the rapid and extremely sensitive measurement of multiple
Updated 06 Jun 2026 16:52
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUxMzk1NjM3NWFkaXF6a2N4 | Paper/PDF filed
Published 08 Jun 2026 23:09
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ1NjM2MzEzOWFkaXF6a2N4
Published 25 Feb 2025 17:02
PSC07 | Transaction MzQ1NjM2MTY2NGFkaXF6a2N4
Published 25 Feb 2025 16:47
AA | Transaction MzQ0MTczNTAwOGFkaXF6a2N4
Published 01 Nov 2024 10:28
SH01 | Transaction MzQzMzA4NTk4MWFkaXF6a2N4
Published 22 Aug 2024 10:29
SH01 | Transaction MzM3MDk3NzE0MWFkaXF6a2N4 | Paper/PDF filed
Published 08 Jun 2026 23:06
SH01 | Transaction MzM2MDk3MTc4M2FkaXF6a2N4 | Paper/PDF filed
Published 08 Jun 2026 23:04
SH01 | Transaction MzM0OTYzMDM2OWFkaXF6a2N4 | Paper/PDF filed
Published 08 Jun 2026 23:06
SH01 | Transaction MzMzNTI5MzAxMmFkaXF6a2N4 | Paper/PDF filed
Published 08 Jun 2026 23:07
Company registered at Companies House
1 Jun 2025 to 31 May 2026
Aureum Diagnostics proposes to develop a ground-breaking point of care diagnostic assay for early and reliable diagnosis of Traumatic Brain Injury (TBI). The project will use Aureum's proprietary advanced high-sensitivity, rapid, low cost and easy to use biosensor platform to measure key biomarkers of TBI in blood. TBI is an emerging market in diagnostic ...
1 Oct 2023 to 31 Dec 2023
To develop next generation sensors which allow low cost and easy to use diagnostic products to be realised, it is necessary to understand the surface properties of the sensor strips in high detail. This is because it is necessary to attach biological molecules to the sensor surface in order to detect a target in a sample. For example, enzymes, antibodies ...
